In this study, we designed a ROS-responsive anti-PD-L1 peptide-functionalized block copolymer, pep-PAP, to co-assemble with paclitaxel (PTX), forming a synergistic drug delivery system (pep-PAPM@PTX) to combine cancer immunotherapy and chemotherapy (Scheme 1). The gene discussed is CD274; the disease is cancer.